Plan GRADE backgroundGRADE background confidence in estimates (quality of evidence)confidence in estimates (quality of evidence) evidence profilesevidence.

Slides:



Advertisements
Similar presentations
Katrina Abuabara, MD, MA1 Esther E Freeman MD, PhD2;
Advertisements

Risk Analysis Fundamentals and Application Robert L. Griffin International Plant Protection Convention Food and Agriculture Organization of the UN.
Plan GRADE background certainty in evidence (quality, confidence evidence) evidence profiles strength of recommendation exercises in applying GRADE.
Learning Programs to Accelerate the BioPharma Transition Network Meta-analysis What is a network meta-analysis? GRADE approach to confidence in estimates.
Holger Schünemann, MD, PhD From Evidence to EMS Practice: Building the National Model Washington, September 4,
Dallas : CPAP and IPPV In spontaneously breathing preterm infants with respiratory distress requiring respiratory support in the delivery room,
The Science of Guidelines The 7th ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines Holger Schünemann, MD, PhD Italian.
Critically Evaluating the Evidence: Tools for Appraisal Elizabeth A. Crabtree, MPH, PhD (c) Director of Evidence-Based Practice, Quality Management Assistant.
Summarising findings about the likely impacts of options Judgements about the quality of evidence Preparing summary of findings tables Plain language summaries.
Estimation and Reporting of Heterogeneity of Treatment Effects in Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare.
Grading of Recommendations Assessment, Development and Evaluation (GRADE) Methodology.
Journal Club Alcohol and Health: Current Evidence September–October 2004.
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
Dallas 2015 TFQO: Karen Woolfrey COI #261 EVREV 1: Karen Woolfrey COI #261 EVREV 2: Daniel Pichel COI #513 Taskforce: ACS ACS 873: Pre-hospital STEMI Activation.
Interpreting Adverse Signals in Diabetes Drug Development Programs Featured Article: Clifford J. Bailey, Ph.D. Diabetes Care Volume 36: 1-9 July, 2013.
Dallas 2015 TFQO: EVREVs: Aaron Donoghue / Jonathan Duff Taskforce: EIT Teaching Compression-Only CPR.
Critical Appraisal of Clinical Practice Guidelines
Their contribution to knowledge Morag Heirs. Research Fellow Centre for Reviews and Dissemination University of York PhD student (NIHR funded) Health.
Illustrating the GRADE Methodology: The Cather Associated-UTI Case Study TEACH Level II Workshop 5 NYAM August 9 th, 2013 Craig A Umscheid, MD, MSCE, FACP.
This sessions will be interactive. So please sit with people with whom you will enjoy a conversation.
Using GRADEpro to create Evidence Profiles and Summary of Findings Tables Wednesday 19 January to 1330 (PT) Nancy Santesso McMaster University.
Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group
Society of General International Medicine 32 nd Annual Meeting, May 14 th 2009 Elie A. Akl, MD, MPH, PhD David Atkins, MD, MPH Eric Bass, MD, MPH Yngve.
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
Canadian Task Force on Preventive Health Care:
Acute Bacterial Rhinosinusitis. Brief Background Typically follows viral infection Dx is by clinical manifestations Streptococcus pneumoniae, Haemophilus.
Brief summary of the GRADE framework Holger Schünemann, MD, PhD Chair and Professor, Department of Clinical Epidemiology & Biostatistics Professor of Medicine.
Grading Strength of Evidence Prepared for: The Agency for Healthcare Research and Quality (AHRQ) Training Modules for Systematic Reviews Methods Guide.
Systematic Review Module 7: Rating the Quality of Individual Studies Meera Viswanathan, PhD RTI-UNC EPC.
Placebo-Controls in Short-Term Clinical Trials of Hypertension Sana Al-Khatib, MD, MHS Assistant Professor of Medicine Division of Cardiology Duke University.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
Applying the GRADE approach to diagnostic technologies Holger Schünemann for the GRADE working group.
Why Grade the Evidence? target audience for Cochrane reviewstarget audience for Cochrane reviews –clinicians interested in the question –policy makers,
GRADE for reducing adverse outcomes actions to reduce adverse outcomes should be based on confidence in estimates of effectactions to reduce adverse outcomes.
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
Two questions in grading recommendations Are you sure?Are you sure? –Yes: Grade 1 –No: Grade 2 What is the methodological quality of the underlying evidenceWhat.
Why Grade Recommendations? strong recommendationsstrong recommendations –strong methods –large precise effect –few down sides of therapy weak recommendationsweak.
WHO GUIDANCE FOR THE DEVELOPMENT OF EVIDENCE-BASED VACCINE RELATED RECOMMENDATIONS August 2011.
Daniel I. Sessler Department of O UTCOMES R ESEARCH Cleveland Clinic on behalf of POISE-2 Investigators PeriOperative ISchemic Evaluation-2 Trial POISE-2POISE-2.
Why Grade Recommendations? strong recommendationsstrong recommendations –strong methods –large precise effect –few down sides of therapy weak recommendationsweak.
Developing evidence-based guidelines at WHO. Evidence-based guidelines at WHO | January 17, |2 |
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December, 2015.
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
GDG Meeting Wednesday November 9, :30 – 11:30 am.
Dallas 2015 TFQO: Hiroshi Nonogi #254 EVREVs: Hiroshi Nonogi #254 Tony Scott #138 Taskforce: ACS Fibrinolytic and immediate PCI for STEMI 882.
بسم الله الرحمن الرحیم.
Why Grade Recommendations? strong recommendationsstrong recommendations –strong methods –large precise effect –few down sides of therapy weak recommendationsweak.
Considerations in grading a recommendation methodological quality of evidencemethodological quality of evidence likelihood of biaslikelihood of bias trade-off.
GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2014.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Methodological Issues in Implantable Medical Device(IMDs) Studies Abdallah ABOUIHIA Senior Statistician, Medtronic.
Critical Appraisal Course for Emergency Medicine Trainees Module 3 Evaluation of a therapy.
Clinical Practice Guidelines: Can we fix Babel? Eddy Lang Department Chair, Emergency Alberta Health Services Associate Professor University of Calgary.
Please sit beside someone from whom you would like help in solving a problem related to practicing evidence-based health care.
From evidence to Policy: Paediatric guideline development in Kenya Mercy Mulaku.
How Do We Individualize Guidelines in an Era of Personalized Medicine? Douglas K. Owens, MD, MS VA Palo Alto Health Care System Stanford University, Stanford.
Approach to guideline development
for Overall Prognosis Workshop Cochrane Colloquium, Seoul
Why this talk? you will be seeing a lot of GRADE
Conflicts of interest Major role in development of GRADE
Systematic Review Systematic review
Overview of the GRADE approach – selected slides
WHO Guideline development
Effect of beta-blockers on perioperative outcomes in vascular and endovascular surgery: a systematic review and meta-analysis  S Hajibandeh, S Hajibandeh,
Plan GRADE background two steps evidence profiles
Ethical Issues in Medical Writing
Clonidine in Patients Having Noncardiac Surgery
A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned  Robert E.
Systematic Reviews and Meta-Analysis -Part 2-
Gregory Levin, FDA/CDER/OTS/OB/DBIII
Presentation transcript:

Plan GRADE backgroundGRADE background confidence in estimates (quality of evidence)confidence in estimates (quality of evidence) evidence profilesevidence profiles confidence in estimates and recommendationsconfidence in estimates and recommendations

Dilemma: proliferation of systems Solution: common international grading system? GRADE (Grades of recommendation, assessment, development and evaluation)GRADE (Grades of recommendation, assessment, development and evaluation) international groupinternational group –Australian NMRC, SIGN, USPSTF, WHO, NICE, Oxford CEBM, CDC, CC ~ 30 meetings over last twelve years~ 30 meetings over last twelve years (~10 – 50 attendants)(~10 – 50 attendants)

60+ Organizations

GRADE uptake

Confidence in estimate (quality of evidence) no confidence totally confident High Moderate Low Very Low Randomized trials start high confidence Observational studies start low confidence

Determinants of confidence risk of bias –concealment – blinding – loss to follow-up imprecision –wide confidence intervals publication bias

Relative Risk with 95% CI for Vitamin D Non-vertebral Fractures

25% 50% 75% No worries Some concern Serious concern Why are we Pooling?

Relative Risk with 95% CI for Vitamin D Non-vertebral Fractures

Quality judgments: Directness populationspopulations –older, sicker or more co-morbidity interventionsinterventions –warfarin in trials and community outcomesoutcomes –important versus surrogate outcomes –glucose control versus CV events

What can raise confidence? large magnitude can upgrade one levellarge magnitude can upgrade one level –very large two levels common criteriacommon criteria –everyone used to do badly –almost everyone does well –quick action hip replacement for hip osteoarthritiship replacement for hip osteoarthritis mechanical ventilation in respiratory failuremechanical ventilation in respiratory failure

Quality assessment criteria

Nonfatal MI – Fixed Effects

Quality Assessment Summary of Findings Quality Relative Effect (95% CI) Absolute risk difference Outcome Number of participants (studies) Risk of Bias ConsistencyDirectnessPrecision Publication Bias Myocardial infarction 10,125 (9) No serious limitations No serious imitations No serious limitations Not detected High 0.71 (0.57 to 0.86) 1.5% fewer (0.7% fewer to 2.1% fewer) ) Beta blockers in non-cardiac surgery

Mortality – Fixed Effects

Quality Assessment Summary of Findings Quality Relative Effect (95% CI) Absolute risk difference Outcome Number of participants (studies) Risk of Bias ConsistencyDirectnessPrecision Publication Bias Myocardial infarction 10,125 (9) No serious limitations No serious imitations No serious limitations Not detected High 0.71 (0.57 to 0.86) 1.5% fewer (0.7% fewer to 2.1% fewer) Mortality 10,205 (7) No serious limitations Possiblly inconsistent No serious limitations Imprecise Not detected Moderate or low 1.23 (0.98 – 1.55) 0.5% more (0.1% fewer to 1.3% more) Beta blockers in non-cardiac surgery

Stroke – Fixed Effects Total events 75/10,290

Quality Assessment Summary of Findings Quality Relative Effect (95% CI) Absolute risk difference Outcome Number of participants (studies) Risk of Bias ConsistencyDirectnessPrecision Publication Bias Myocardial infarction 10,125 (9) No serious limitations No serious imitations No serious limitations Not detected High 0.71 (0.57 to 0.86) 1.5% fewer (0.7% fewer to 2.1% fewer) Mortality 10,205 (7) No serious limitations Possiblly inconsistent No serious limitations Imprecise Not detected Moderate or low 1.23 (0.98 – 1.55) 0.5% more (0.1% fewer to 1.3% more) Stroke 10,889 (5) No serious limitaions No serious limitations Not detected High 2.21 (1.37 – 3.55) 0.5% more (0.2% more to 1.3% more0 Beta blockers in non-cardiac surgery

Significance of strong vs weak variability in patient preferencevariability in patient preference –strong, almost all same choice (> 90%) –weak, choice varies appreciably interaction with patientinteraction with patient –strong, just inform patient –weak, ensure choice reflects values use of decision aiduse of decision aid –strong, don’t bother –weak, use the aid quality of care criterionquality of care criterion –strong, consider –weak, don’t consider

Strength of Recommendation strong recommendation –benefits clearly outweigh risks/hassle/cost –risk/hassle/cost clearly outweighs benefit what can downgrade strength? low confidence in estimates close balance between up and downsides

Conclusion clinicians, policy makers need summariesclinicians, policy makers need summaries –quality of evidence explicit rulesexplicit rules –transparent, informative GRADEGRADE –simple, transparent, systematic